RETINOPATHY OF PREMATURITY: NICU TO ADULTHOOD: Edited by Audina Berrocal and Antonio Capone Jr.Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapyValikodath, Nita G.a; Chiang, Michael F.b; Chan, R.V. PaulaAuthor Information aDepartment of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois bNational Eye Institute, National Institutes of Health, Bethesda, Maryland, USA Correspondence to R.V. Paul Chan, MD, MSc, MBA, 1905 W. Taylor St, Chicago, IL 60612, USA. Tel: +1 312 996 6590; fax: +1 312 996 7770; e-mail: [email protected] Current Opinion in Ophthalmology: September 2021 - Volume 32 - Issue 5 - p 468-474 doi: 10.1097/ICU.0000000000000786 Buy Metrics Abstract Purpose of review To review the literature regarding reactivation of retinopathy of prematurity (ROP) after treatment with antivascular endothelial growth factor (anti-VEGF) agents. Recent findings Reactivation can occur after anti-VEGF or laser. Risk factors for reactivation include patient and disease-related factors. Various studies are evaluating the use of different anti-VEGF agents and reactivation rates. However, the definition of reactivation varies between studies. Summary The literature has varied definitions of reactivation, which is often used interchangeably with recurrence. It is important to recognize features of reactivation of ROP to appropriately manage patients and conduct clinical trials. The International Classification of ROP 3rd edition has established a consensus guideline regarding terminology describing reactivation. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.